Buck researchers identify new 'druggable' target for sporadic Parkinson's disease
Research at the Buck Institute shows the same mechanisms that lead to neuronal cell death in mice genetically fated to develop Parkinson's disease (PD) are involved in the much more common sporadic form of the age-related, neurodegenerative disorder that robs people of the ability to move normally. The research identifies new targets that show promise for drug development for an incurable condition that affects as many as one million Americans.
The study focused on parkin - a protein involved in the degradation and purging of both damaged proteins and mitochondria via a process known as lysosomal autophagy. Mutations of parkin are linked to a rare familial form of PD, whereby the cell loses the ability to recycle its internal garbage. PD is characterized by the accumulation of damaged proteins and mitochondria in the area of the brain where the neurotransmitter dopamine is produced.
In this study scientists, led by Buck faculty Julie Andersen, PhD, showed that oxidative stress, which is one of the main drivers of sporadic PD, affected the parkin protein in the same way that genetic mutations do. "This gives us a significant insight into sporadic PD which accounts for 95 percent of all cases of the disease," said Andersen. "We also determined that the signaling pathway involved in the molecular dysfunction is a good target for drug development."
The pathway involves two master regulatory proteins, PGC-1alpha which affects the synthesis of new mitochondria and TFEB which is involved in breaking down old mitochondria. Both are down-regulated following oxidative stress. When scientists genetically increased the expression of PGC-1alpha in the affected mice, mitochondrial function was restored, preventing the degeneration of dopaminergic neurons affected by PD.
Researchers in the Andersen and Lithgow labs are now screening compounds in human cell culture and in nematode worms that have been genetically engineered to develop PD-like characteristics. The goal is to identify compounds that target the pathway and prevent the neurotoxic damage associated with the disease.
Original publication
Most read news
Original publication
Almas Siddiqui, Anand Rane, Subramanian Rajagopalan, Shankar J. Chinta, Julie K. Andersen; "Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson's disease are attenuated by restoration of PGC1alpha"; Neurobiology of Disease; 2016
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Modified crops reveal hidden cost of resistance

Bristol-Myers Squibb names Peter J. Arduini to board of directors
QIAGEN launches coronavirus test kit in Germany following derogation by BfArM
Nobel Biocare appoints William J. Ryan as Senior Advisor to the Chief Executive Officer
Stem cell therapy makes cloudy corneas clear, according to Pitt researchers
Plant Sacrifices Cells to Fight Invaders - Gene ensures programmed cell suicide does not go unchecked
GeneProt Expands its Proteomic Capabilities Through a New Scientific Agreement - GeneProt amends its collaboration with Novartis Pharma

No more binge eating: signal pathway in the brain that controls food intake discovered - Specific inhibitors of lipid synthesis could serve as new obesity therapies
